Kamada Ltd. (NASDAQ: KMDA) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 20.59 | EPS (ttm) | 0.35 | Insider Own | 0.88% | Shs Outstand | 57.69M | Perf Week | 1.82% |
| Market Cap | 419.44M | Forward P/E | 11.85 | EPS next Y | 0.61 | Insider Trans | 0.00% | Shs Float | 31.45M | Perf Month | 1.68% |
| Enterprise Value | 398.16M | PEG | 1.00 | EPS next Q | - | Inst Own | - | Short Float | 0.42% | Perf Quarter | -11.99% |
| Income | 19.92M | P/S | 2.31 | EPS this Y | 22.14% | Inst Trans | - | Short Ratio | 2.92 | Perf Half Y | -9.35% |
| Sales | 181.68M | P/B | 1.65 | EPS next Y | 43.47% | ROA | 5.32% | Short Interest | 130.69K | Perf YTD | 2.97% |
| Book/sh | - | P/C | 16.53 | EPS next 5Y | 17.68% | ROE | 7.73% | 52W High | 9.11 -22.25% | Perf Year | 3.71% |
| Cash/sh | - | P/FCF | 25.37 | EPS past 3/5Y | - -2.03% | ROIC | 7.14% | 52W Low | 6.33 11.85% | Perf 3Y | 47.17% |
| Dividend Est. | 0.25 (3.53%) | EV/EBITDA | 10.41 | Sales past 3/5Y | 11.74% 6.24% | Gross Margin | 41.16% | Volatility | 2.25% 2.04% | Perf 5Y | 33.64% |
| Dividend TTM | 0.25 (3.53%) | EV/Sales | 2.19 | EPS Y/Y TTM | 40.00% | Oper. Margin | 13.98% | ATR (14) | 0.17 | Perf 10Y | 83.59% |
| Dividend Ex-Date | Mar 23, 2026 | Quick Ratio | 1.90 | Sales Y/Y TTM | 13.04% | Profit Margin | 11.21% | RSI (14) | 52.85 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.33 | EPS Q/Q | 0.00% | SMA20 | 2.10% | Beta | 0.87 | Target Price | 13.00 |
| Payout | 55.45% | Debt/Eq | 0.04 | Sales Q/Q | 2.27% | SMA50 | 0.07% | Rel Volume | 0.39 | Prev Close | 7.27 |
| Employees | 462 | LT Debt/Eq | 0.03 | Earnings | Aug 12 | SMA200 | -5.83% | Avg Volume | 45.10K | Price | 7.08 |
| IPO Date | May 31, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -39.13% -3.17% | Net Debt/EBITDA | -0.56 | Volume | 17,722 | Change | -2.54% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-21-26 | Reiterated | William Blair | $15 | |
| Mar-11-26 | Reiterated | Stifel Nicolaus | $20 → $11 | |
| Dec-09-25 | Reiterated | HC Wainwright & Co. | Buy | $13 |
| Nov-13-24 | Reiterated | Stifel Nicolaus | $20 |
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 182 | 180 | 161 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 107 | 104 | 91 | — | — | — | — | — | — | |
| Gross Profit | 75 | 76 | 70 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 34 | 31 | — | — | — | — | — | — | |
| Research and Development | 11 | 13 | 15 | — | — | — | — | — | — | |
| Other Operating Expense | 3 | 3 | 4 | — | — | — | — | — | — | |
| Operating Income | 26 | 26 | 20 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 1 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | -2 | -6 | — | — | — | — | — | — | |
| Net Income Before Taxes | 22 | 23 | 13 | — | — | — | — | — | — | |
| Income Taxes | 1 | 3 | -1 | — | — | — | — | — | — | |
| Consolidated Net Income | 20 | 20 | 14 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 20 | 20 | 14 | — | — | — | — | — | — | |
| Net Income | 20 | 20 | 14 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.35 | 0.38 | 0.25 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.35 | 0.38 | 0.25 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.35 | 0.37 | 0.25 | — | — | — | — | — | — | |
| EBITDA | 38 | 39 | 28 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 20.24 | 19.08 | 24.36 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.30 | 2.27 | 2.16 | — | — | — | — | — | — | |
| Gross Margin | 41.21 | 42.22 | 43.48 | — | — | — | — | — | — | |
| Operating Margin | 14.29 | 14.44 | 12.42 | — | — | — | — | — | — | |
| Net Margin | 10.99 | 11.11 | 8.70 | — | — | — | — | — | — | |
| Shares Outstanding | 59 | 58 | 57 | — | — | — | — | — | — | |
| Market Capitalization | 418 | 409 | 347 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |